These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12201954)

  • 21. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.
    Rajasekar R; Mathews V; Lakshmi KM; Sellathamby S; George B; Viswabandya A; Daniel D; Chandy M; Srivastava A
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):344-50. PubMed ID: 18275901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy.
    Ward KA; Stewart LA; Schwarer AP
    Cytotherapy; 2006; 8(2):130-40. PubMed ID: 16698686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.
    Baron F; Schaaf-Lafontaine N; Humblet-Baron S; Meuris N; Castermans E; Baudoux E; Frère P; Bours V; Fillet G; Beguin Y
    Transplantation; 2003 Dec; 76(12):1705-13. PubMed ID: 14688520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Rzepecki P; Sarosiek T; Szczylik C
    Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia.
    Auffermann-Gretzinger S; Eger L; Schetelig J; Bornhäuser M; Heidenreich F; Ehninger G
    Transplantation; 2007 May; 83(9):1268-72. PubMed ID: 17496545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells in allogeneic hematopoietic stem cell transplantation.
    Nachbaur D; Kircher B
    Leuk Lymphoma; 2005 Oct; 46(10):1387-96. PubMed ID: 16194884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Theil K; Serafino S; Rybicki L; Kalaycio M
    Bone Marrow Transplant; 2003 Jan; 31(2):95-8. PubMed ID: 12621489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
    Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method.
    Szabolcs P; Park KD; Reese M; Marti L; Broadwater G; Kurtzberg J
    Stem Cells; 2003; 21(3):296-303. PubMed ID: 12743324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of G-CSF mobilisation on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation.
    Hock BD; Haring LF; Ebbett AM; Patton WN; McKenzie JL
    Bone Marrow Transplant; 2002 Dec; 30(11):733-40. PubMed ID: 12439695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Mayani H; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR
    Ann Hematol; 2006 May; 85(5):308-14. PubMed ID: 16525786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli.
    Chen B; Stiff P; Sloan G; Kash J; Manjunath R; Pathasarathy M; Oldenburg D; Foreman KE; Nickoloff BJ
    Clin Immunol; 2001 Feb; 98(2):280-92. PubMed ID: 11161986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.